Replimune Group (REPL) Competitors $9.45 -0.10 (-1.05%) Closing price 07/3/2025 03:03 PM EasternExtended Trading$9.48 +0.03 (+0.26%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. CRNX, VKTX, ALVO, CPRX, HCM, IMVT, OGN, MIRM, AMRX, and IBRXShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Immunovant (IMVT), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors Crinetics Pharmaceuticals Viking Therapeutics Alvotech Catalyst Pharmaceuticals HUTCHMED Immunovant Organon & Co. Mirum Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Crinetics Pharmaceuticals (NASDAQ:CRNX) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has more risk and volatility, CRNX or REPL? Crinetics Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Which has better earnings and valuation, CRNX or REPL? Replimune Group has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M2,689.61-$298.41M-$3.82-7.82Replimune GroupN/AN/A-$247.30M-$3.07-3.08 Do institutionals & insiders have more ownership in CRNX or REPL? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate CRNX or REPL? Crinetics Pharmaceuticals currently has a consensus price target of $71.75, indicating a potential upside of 140.17%. Replimune Group has a consensus price target of $20.83, indicating a potential upside of 120.46%. Given Crinetics Pharmaceuticals' higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is CRNX or REPL more profitable? Crinetics Pharmaceuticals' return on equity of -30.95% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% Replimune Group N/A -57.98%-45.21% Does the media favor CRNX or REPL? In the previous week, Replimune Group had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Replimune Group and 2 mentions for Crinetics Pharmaceuticals. Replimune Group's average media sentiment score of 0.31 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryReplimune Group beats Crinetics Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$724.61M$2.89B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-3.0821.7127.6620.25Price / SalesN/A281.81415.41118.18Price / CashN/A42.7336.8958.07Price / Book1.757.518.035.67Net Income-$247.30M-$55.14M$3.18B$249.21M7 Day Performance1.29%4.61%2.93%3.27%1 Month Performance-3.08%4.72%3.75%5.55%1 Year Performance16.52%5.92%35.20%21.08% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.1885 of 5 stars$9.45-1.0%$20.83+120.5%+16.8%$724.61MN/A-3.08210News CoverageAnalyst ForecastCRNXCrinetics Pharmaceuticals3.3069 of 5 stars$29.91-0.8%$74.56+149.3%-32.4%$2.80B$760K-7.83210VKTXViking Therapeutics4.3593 of 5 stars$24.86-4.4%$87.15+250.6%-44.2%$2.79BN/A-21.6220Trending NewsInsider TradeALVOAlvotech3.5295 of 5 stars$9.13-2.4%$18.00+97.2%-24.4%$2.75B$491.98M24.681,032CPRXCatalyst Pharmaceuticals4.9184 of 5 stars$22.12-1.6%$32.83+48.4%+41.3%$2.70B$491.73M14.0980Positive NewsHCMHUTCHMED1.3561 of 5 stars$15.21+2.5%$19.00+24.9%-9.3%$2.65B$630.20M0.001,811IMVTImmunovant1.418 of 5 stars$15.47-2.1%$38.33+147.8%-35.9%$2.64BN/A-5.65120OGNOrganon & Co.4.8953 of 5 stars$9.82+0.7%$18.00+83.3%-50.4%$2.55B$6.40B3.414,000Trending NewsMIRMMirum Pharmaceuticals3.7333 of 5 stars$50.28-0.1%$65.50+30.3%+47.4%$2.49B$336.89M-31.23140News CoveragePositive NewsAMRXAmneal Pharmaceuticals3.2096 of 5 stars$7.91+1.2%$11.60+46.6%+26.8%$2.48B$2.79B-197.708,100IBRXImmunityBio1.8594 of 5 stars$2.76-3.8%$12.25+343.8%-57.0%$2.44B$14.74M-4.76590Negative NewsGap Up Related Companies and Tools Related Companies Crinetics Pharmaceuticals Alternatives Viking Therapeutics Alternatives Alvotech Alternatives Catalyst Pharmaceuticals Alternatives HUTCHMED Alternatives Immunovant Alternatives Organon & Co. Alternatives Mirum Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives ImmunityBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
